Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879329 · ClinicalTrials.gov registry record · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Phase 2 study of Urothelial Carcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 372
- Enrollment target
- 20
- Study locations
NCT04879329 is a Phase 2 study of Urothelial Carcinoma that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 372 participants, above the 235-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT04879329, a Phase 2 study of Urothelial Carcinoma, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 372 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG disitamab vedotin
Study Locations (20)
California
- Kaiser Permanente Anaheim Kraemer Medical Offices - Anaheim
- Foothill Cardioology - Arcadia
- Kaiser Permanente Baldwin Park Medical Center - Baldwin Park
- Kaiser Permanente Bellflower Medical Offices - Bellflower
- Beverly Hills Multi-Specialties Practice - Beverly Hills
- Providence Saint Joseph Medical Center - Burbank
- UCLA Burbank Cardiology - Burbank
- UCLA Hematology/Oncology - Burbank - Burbank
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
- UCLA Encino Specialty Care (Radiology) - Encino
- UCLA Hematology/Oncoclogy-Encino - Encino
- Kaiser Permanente Fontana Medical Center - Fontana
- Foothill Cardiology Glendora - Glendora
- Kaiser Permanente South Bay Medical center - Harbor City
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Kaiser Permanente Alton/Sand Canyon Medical Offices - Irvine
- UCLA Downtown Los Angeles Primary & Specialty Care - Los Angeles
- Kaiser Permanente Los Angeles Medical Offices - Los Angeles
Arizona
- Banner Gateway Medical Center - Gilbert
- Banner MD Anderson Cancer Center - Gilbert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2029-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04879329
The ClinicalTrials.gov registry entry for NCT04879329 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (58% higher). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04879329 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04879329 about?
NCT04879329 is a clinical study titled "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2". This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanc...
What is the current status of trial NCT04879329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2022-05-03. Estimated completion is 2029-04-14.
What conditions does trial NCT04879329 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT04879329?
The interventions under investigation include: pembrolizumab (DRUG), disitamab vedotin (DRUG).
Who is sponsoring clinical trial NCT04879329?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04879329 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Circulating Tumor DNA Response In Urothelial Cancer
RECRUITING · Phase 2
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
RECRUITING · Phase 2
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.